Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes

Tonya L Breaux-Shropshire, Eric Judd, Lee A Vucovich, Toneyell S Shropshire, Sonal Singh

Objective: Our objective was to compare the clinical effectiveness of home blood pressure monitoring (HBPM) and 24-hour ambulatory blood pressure monitoring (ABPM) on blood pressure (BP) control and patient outcomes.

Design: A systematic review was conducted. We also appraised the methodological quality of studies.

Data sources: PubMed, Scopus, CINAHL, and the Cochrane Central Register of Control Trials (CENTRAL).

Inclusion criteria: Randomized control trials, prospective and retrospective cohort studies, observational studies, and case-control studies published in English from any year to present that describe HBPM and 24-hour ABPM and report on systolic and/or diastolic BP and/or heart attack, stroke, kidney failure and/or all-cause mortality for adult patients. Due to the nature of the question, studies with only untreated patients were not considered.

Results: Of 1,742 titles and abstracts independently reviewed by two reviewers, 137 studies met predetermined criteria for evaluation. Nineteen studies were identified as relevant and included in the paper. The common themes were that HBPM and ABPM correlated with cardiovascular events and mortality, and targeting HBPM or ABPM resulted in similar outcomes. Associations between BP measurement type and mortality differed by study population. Both the low sensitivity of office blood pressure monitoring (OBPM) to detect optimal BP control by ABPM and the added association of HBPM with cardiovascular mortality supported the routine use of HBPM in clinical practice. There was insufficient data to determine the benefit of using HBPM as a measurement standard for BP control.

Conclusion: HBPM encourages patient-centered care and improves BP control and patient outcomes. Given the limited number of studies with both HBPM and ABPM, these measurement types should be incorporated into the design of randomized clinical trials within hypertensive populations.

Keywords: ABPM, HBPM, OBPM, randomized control trials

Introduction

Based on scientific evidence, national and international guidelines recommend optimizing medication dosages or adding additional antihypertensive medication until target goal blood pressure (BP) is obtained. Obtaining a target goal BP is crucial to prevent poor outcomes such as cardiovascular disease, kidney failure, and stroke. However, approximately 53.5% of Americans are not at their target goal BP. While office blood pressure monitoring (OBPM) is the usual care or gold standard for hypertension...
The Jaded scale was used as a means of assessing the research methodology and scientific merit of randomized control trials. The Jaded scale is a validated scale that measures methodological quality. Differences in data extraction were resolved by consensus. Data extraction form was with explicit instructions that was created prior to the article review to ensure that both reviewers complete the form consistently. An evidence table was created to display the systematic overview of all studies lining up relevant data.
study quality by assigning a numeric score ranging from 1 to 5 based on methodological indicators such as randomization, double blinding, and descriptions of participant dropout data. Observational studies were assessed using Newcastle–Ottawa Scales.

Data synthesis

Relevant data were synthesized qualitatively to combine the results and to draw conclusions from the findings. Data limitations prevented subgroup analyses. Subgroup analyses were not performed due to a limited number of studies with identical or similar outcomes.

Results

Study characteristics

From the search, 19 studies were included in this systematic review. Studies were grouped into three main categories by study outcome: mortality, target organ damage, and BP control (Table 1). Five studies investigated associations between BP measurement type (e.g., OBPM, HBPM, and ABPM) and mortality. These studies consisted of observational analyses in distinct populations, including patients with CKD or end-stage kidney disease in the United States, patients ≥60 years of age from a single primary care practice in Belgium, and the general populations in Japan and Italy. Sample sizes ranged from 210 to 2,051 participants with median follow-up times between 2.4 and 12.3 years (Table 1).

Four studies compared target organ damage between the different BP measurement types. Target organ damage was measured as urine albumin-to-creatinine ratio, left ventricular hypertrophy by either electrocardiogram or echocardiogram, pulse wave velocity, or flow-mediated dilation of the brachial artery. Two studies were cross-sectional analyses with a single time point of data collection, and two were prospective designs with follow-up times of 6 and 12 months. Sample sizes ranged from 59 to 854 participants (Table 1).

The remaining ten studies contained all three types of BP measurement (OBPM, HBPM, and ABPM) and BP control data. Two were cross-sectional observational analyses, five were randomized controlled trials, and three were quasi-experimental studies without an active intervention or a control group. The majority of study populations consisted of individuals with mild-to-moderate hypertension, either treated or untreated. Trials were short in length ranging from 4 weeks to 6 months. Antihypertensive medication formed the intervention for three of the five randomized controlled trials. Two trials randomized participants to have their BP medication adjusted according to HBPM vs OBPM or HBPM vs ABPM.

Study findings

The major findings of each study are summarized in Table 1. Associations between BP measurement type (e.g., OBPM, HBPM, and ABPM) and mortality differ by study population. In patients with CKD or end-stage kidney disease, ABPM is a superior predictor of mortality. For persons ≥60 years of age, HBPM is as good or better than ABPM when predicting mortality in older patients. In the general population, additional BP information regardless of measurement type (OBPM, HBPM, and ABPM) contributes to cardiovascular risk. However, only BP assessed by HBPM and ABPM is associated with all-cause mortality.

Data describing associations between BP measurement type and target organ damage are limited with only four studies meeting inclusion criteria. In general, arterial stiffness (measured by pulse wave velocity, albuminuria, and left ventricular mass were associated with changes in BP regardless of measurement type. Regarding BP control, benefits emerge when including HBPM. In patients receiving hemodialysis, targeting antihypertensive treatment to home BPs as opposed to predialysis BP results in better BP control, as assessed by ABPM. Fuchs et al showed that merely randomizing an individual to HBPM and not making any antihypertensive medication adjustments improves BP control. Using HBPM to titrate antihypertensive medication produces the same level of control as using ABPM.

Targeting OBPM for control is limited by the low sensitivity of office BP to detect optimal BP control defined by

Figure 1 Flow diagram.
either HBPM or ABPM (50% and 53.4%, respectively). Many studies agree that the correlation between HBPM and ABPM is stronger than that of OBPM with ABPM. However, in the general hypertensive population, HBPM can result in fewer prescribed medications with less BP control.

### Discussion

The systematic selection of studies containing both HBPM and ABPM produced only 19 unique studies with a combined number of study participants near 7,100. Data were too limited to determine the benefit of using HBPM as a BP target when adjusting antihypertensive medications. This lack of data in the highly studied hypertensive population is a major finding in and of itself. However, clinically relevant conclusions can still be drawn from our review.

All of the studies that evaluated the relationship between OBPM, HBPM, and ABPM found HBPM to be correlated with ABPM and this correlation was stronger than that of OBPM and ABPM. This agreement in combination with the
<table>
<thead>
<tr>
<th>Outcome(s)</th>
<th>Major findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Quartiles of SBP were strongly related to the hazard ratio for all-cause mortality with ABPM, less strongly with HBPM, and not related with dialysis-unit BP</td>
</tr>
<tr>
<td>Combined total mortality, MI, and stroke</td>
<td>Only HTN defined by ABPM predicted cardiovascular outcomes, whereas definitions based on in-clinic BP or HBPM did not predict CV outcomes</td>
</tr>
<tr>
<td>Combined cardiovascular death, MI, or stroke</td>
<td>SBP by HBPM and ABPM predicted major cardiovascular events while office SBP did not</td>
</tr>
<tr>
<td>All-cause mortality, cardiovascular mortality</td>
<td>Prognostic value of home BP was equal to (SBP) or better than (DBP) that of daytime BP by ABPM</td>
</tr>
<tr>
<td>Cardiovascular and non-cardiovascular mortality</td>
<td>BP assessed by HBPM and ABPM was associated with mortality, while casual BP screening was not</td>
</tr>
</tbody>
</table>

| UACR, LVH by ECG | One year changes in SBP were closer between HBPM and daytime ABPM than clinic measurement. No changes in UACR or LVH by ECG were seen |
| LVH by echocardiogram | LVH was more prevalent among participants with uncontrolled office BP compared with controlled office BP, despite similar control by ABPM and HBPM |
| FMD, PWV, UACR | Changes in PWV and UACR were associated with changes in BP regardless of measurement type. Changes in FMD were only associated with changes in BP by HBPM |
| UACR, LVPl mass index | SBP measured by ABPM, HBPM, and clinic was associated with natural log-transformed UACR and LV mass index. Correlation with UACR was strongest for SBP by HBPM |

| BP control | Participants randomized to HBPM had higher SBP by ABPM and fewer BP medications when compared with usual care |
| BP control | Office BP overestimated SBP response to therapy by an average of 4.6 mmHg when compared with home BP. Correlation with ABPM was higher for home compared with office BP (r=0.58 and 0.47, respectively) |
| BP control, LV mass index | Adjusting antihypertensive therapy by HBPM as opposed to predialysis BP measurement resulted in a greater reduction in SBP by ABPM (135±12 vs 147±15 mmHg, \( P<0.05 \)) |
| BP control | No difference was seen in LV mass index |
| BP control | Conventional office BP had a low sensitivity to detect optimal BP control by either HBPM or ABPM (50% and 53.4%, respectively) |
| BP control | Randomizing participants to HBPM without medication titration improves BP control by ABPM (32.4% vs 16.2% control rates, respectively; \( P=0.03 \)) |
| BP control | BP control was similar when assessed by clinic, HBPM, or ABPM |
| BP control | BP reductions were similar for HBPM and ABPM |
| BP control | Change in mean SBP and DBP as measured by HBPM and ABPM were correlated (\( r=0.4, P<0.05 \) for \( \Delta \)SBP; \( r=0.6, P<0.0005 \) for \( \Delta \)DBP) |
| BP control | No difference was seen in BP control when randomized to antihypertension medication adjustment by HBPM or ABPM |
| BP control | BP reductions were poorly correlated between office monitoring and ABPM (\( r=0.05 \) for \( \Delta \)SBP). Correlation of \( \Delta \)SBP between HBPM and ABPM was 0.14 |

Low sensitivity of office BP to detect optimal BP control by ABPM and the added association of HBPM with cardiovascular mortality all support the use of HBPM when treating hypertension. It is not surprising that routine use of HBPM has been recommend for almost a decade. Currently, the American Heart Association, the American Society of Hypertension, and the Preventive Cardiovascular Nurses Association suggest that HBPM be incorporated into usual care.

By comparison, HBPM has some advantages over ABPM. The availability of affordable BP monitoring devices has allowed individuals to measure and record BPs repeatedly throughout their course of treatment. In contrast, ABPM is not directly available to patients, and its high cost presents a barrier to initial and repeated testing. By requiring the individual to wear the cuff and monitor continuously, ABPM does interfere with daily activities and sleep. Although, any advantage in convenience or comfort with HBPM is weighed against the superior standardization of BP measurement and the acquisition of sleep-time BP data by 24-hour ABPM.
It is important to note that large randomized trials investigating hypertension treatment have targeted BP measured during study visits, similar to OBPM, when evaluating medication efficacy and participant outcomes. For this reason, HBPM should not supplant OBPM. While the addition of HBPM will help physicians to identify patients with masked-uncontrolled hypertension (ie, individuals controlled in the office yet uncontrolled at home), in patients with low home BPs, HBPM data can adversely affect treatment decisions. The study by Bailey et al offers a reminder to physicians that care must be taken when incorporating HBPM data into treatment strategies. Physician behavior was influenced by HBPM readings and resulted in fewer prescribed medications; systolic BP by 24-hour ABPM was 137±3 mmHg for the group randomized to HBPM compared with 130±3 mmHg in the usual care group.37

However, HBPM can improve BP control through its indirect effects on patients. HBPM encourages patient-centered care. Self-monitoring of BP reminds patients of the importance of medication adherence and healthy lifestyle factors. The study by Fuchs et al supports these indirect effects of self-monitoring. Participating in HBPM alone improved BP control.38

Limitations
In the review process, we identified numerous studies with both HBPM and ABPM data that were designed as validation studies for BP monitoring devices. While these studies do contain information regarding BP control, they did not align with our interpretation of the outcome of BP control. Variability existed in the timing of HBPM both in the length of monitoring time (2–14 days) and in the frequency of measurement (two to six times per day). On the other hand, ABPM was more consistent with measurements every 15–20 minutes while awake and 15–30 minutes while asleep for a total of 24–44 hours.

An important distinction between HBPM and ABPM is the inclusion of nocturnal measurements with ABPM. We did not pursue outcome associations with isolated nocturnal hypertension. Furthermore, this study examined the effect of BP measurement type on BP control and clinical outcomes, yet did not attempt to answer the question of what is the goal BP.

Conclusion
Our findings support the guideline recommendations to include HBPM in the management of hypertension. The benefits of identifying masked-uncontrolled hypertension and increasing patient participation in his/her care outweigh the risk of undertreating patients with white coat phenomena.

Disclosure
The authors report no conflicts of interest in this work.

References


